Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

Background: The purpose of this study is to evaluate the impact on the health-related quality of life (HRQoL) of sunitinib versus interferon-alpha (IFN-α) treatment in patients with metastatic renal cell carcinoma (mRCC). Patients and methods: In all, 304 mRCC patients (European cohort) were randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellano, D., del Muro, X. Garcia, Pérez-Gracia, J. L., González-Larriba, J. L., Abrio, M. V., Ruiz, M. A., Pardo, A., Guzmán, C., Cerezo, S. Díaz, Grande, E.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768734/
https://www.ncbi.nlm.nih.gov/pubmed/19549706
http://dx.doi.org/10.1093/annonc/mdp067

Ejemplares similares

Ejemplares similares